When Karen was diagnosed with triple-negative breast cancer, she researched different treatments and oncologists, sought out second and third opinions, and found a care team that she trusted. #CIM21 #Immune2Cancer #CancerStory
Following surgery and chemotherapy for stage 1 triple-negative breast cancer, Karen took charge of her cancer narrative by researching other treatment options and talking to experts during a brief period of remission. When her cancer returned in 2017—this time metastatic—she was facing a life expectancy of 18 to 24 months, but she was prepared to try something new. She enrolled as the first patient in a phase 1 trial at NYU Langone’s Perlmutter Cancer Center combining two immunotherapies: bempegaldesleukin (BEMPEG; NKTR-214) and nivolumab (Opdivo®). Her first CT scan, after eight weeks of immunotherapy, revealed a 72% reduction in tumors. In June 2020, Karen’s oncologist declared her “an official complete responder.” Impassioned by her experience, she is now a patient advocate and educator, helping others find their voice in cancer care. [ Ссылка ]
This video is part of the 9th Annual Cancer Immunotherapy Month™ in June 2021, hosted by the Cancer Research Institute. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. [ Ссылка ]
Immunotherapy patient stories are part of the Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. [ Ссылка ]
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
